Viking Therapeutics (VKTX) Research & Development (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Research & Development data on file, last reported at $150.2 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 262.76% year-over-year to $150.2 million; the trailing twelve-month figure through Mar 2026 stood at $453.7 million (up 281.49% YoY), and the FY2025 full-year result was $345.0 million, up 239.38% from the prior year.
• Research & Development retreated to $150.2 million in Q1 2026, from $153.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $153.5 million in Q4 2025 to a low of $11.0 million in Q1 2023.
• A 5-year average of $42.0 million and a median of $22.8 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development slipped 12.32% in 2023 and jumped 395.24% in 2025, its largest moves.
• Tracing VKTX's Research & Development over 5 years: stood at $16.2 million in 2022, then climbed by 26.73% to $20.5 million in 2023, then surged by 51.14% to $31.0 million in 2024, then jumped by 395.24% to $153.5 million in 2025, then declined by 2.16% to $150.2 million in 2026.
• Business Quant data shows VKTX's Research & Development at $150.2 million in Q1 2026, $153.5 million in Q4 2025, and $90.0 million in Q3 2025.